arrow
M

Michiel Coppens

Department of Vascular Medicine
H指数:41
被引数:8,472

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Psychometric properties and outcomes of the PROMIS® Sexual Function and Satisfaction measures in individuals with congenital bleeding disorders

PROMIS®性功能与满意度量表的测量属性和结果:先天性出血障碍患者研究

2026-09-020
OAAI
Plasma protein profile in patients with antiphospholipid syndrome and controls without APS

抗磷脂综合征患者和未患APS对照组的血浆蛋白质谱

2026-08-310
OA
Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: Interim Analysis of the DosEmi Study

先天性血友病A中基于药代动力学的依米珠单抗剂量调整:DosEmi研究的期中分析

2025-11-070
OAAI
Diagnostic accuracy of CT venography compared to ultrasonography for detection of peripherally inserted central venous catheter-related thrombosis in patients with cancer: the DETECT study

CT静脉造影与超声检查在检测癌症患者经外周静脉置入中心静脉导管相关血栓方面的诊断准确性比较:DETECT研究

2025-08-270
OAAI
Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe

Edoxaban治疗静脉血栓栓塞超过18个月: 来自etna-vte Europe的结果

2025-01-160
OAAI
Postpartum Hemorrhage in Hemophilia a and B Carriers after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)

产后期血友病A和B携带者在使用强化预防性凝血因子补充疗法后的产后出血:妊娠与遗传性出血性疾病研究(PRIDES)

BLOOD
IF23.1
2024-11-050
PRE
The Influence of Postpartum Hemorrhage on Patient Reported Outcomes Among Women with Von Willebrand Disease: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)

产后出血对患有冯·维勒布兰德病女性患者报告结局的影响:妊娠与遗传性出血障碍研究(PRIDES)

BLOOD
IF23.1
2024-11-050
PRE
Pharmacokinetic-Guided Reduction of Emicizumab in Patients with Congenital Hemophilia a in the Netherlands: Interim Analysis from the Dosemi Study

荷兰先天性血友病A患者中基于药代动力学的依米珠单抗减量:Dosemi研究的期中分析

BLOOD
IF23.1
2024-11-050
PRE
Postpartum Hemorrhage in Women with Von Willebrand Disease after Enhanced Prophylactic Clotting Factor Suppletion: The Pregnancy and Inherited Bleeding Disorders Study (PRIDES)

在应用增强性预防性凝血因子补充治疗后,冯·维勒布兰德病女性产后出血情况:妊娠与遗传性出血性疾病研究(PRIDES)

BLOOD
IF23.1
2024-11-050
PRE
Primary postpartum hemorrhage in women with von Willebrand disease and carriers of hemophilia: a retrospective analysis
2024-07-010
OAAI
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

Etranacogene dezaparvovec基因治疗血友病B (hope-b): 来自单臂,多中心,3期试验的24个月事后疗效和安全性数据

2024-04-017
PRE
Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B

药代动力学指导的血友病A和B因子浓缩物预防性给药的预测性能

2024-03-010
OAAI